The Estrobolome: How Your Gut Bacteria Regulate Your Estrogen

Most conversations about estrogen focus on the ovaries, and for good reason. The ovaries are the primary production site for estradiol in premenopausal women. But production is only half the story. Once estrogen has done its job, your body needs to process it and get rid of it. That clearance process runs through your liver, which tags estrogen for removal, and then through your gut, which is supposed to escort it out. The problem is that certain gut bacteria can intercept that process. They produce an enzyme called beta-glucuronidase that strips the liver's tag off estrogen, sending it back into your bloodstream instead of out in your stool. The collection of bacteria responsible for this is called the estrobolome, a term coined in a 2011 paper by Plottel and Blaser that has since reshaped how researchers think about hormone metabolism.

What is the estrobolome and how does it work?

The estrobolome is not a single organism or a single gene. It is the total set of gut bacteria that are capable of producing beta-glucuronidase, the enzyme that modifies estrogen metabolism in the intestines. The concept was formally introduced by Plottel and Blaser in the Journal of Steroid Biochemistry and Molecular Biology in 2011, and it drew on decades of earlier observations about how antibiotics could alter urinary estrogen excretion (Adlercreutz et al., 1984).

Here is the basic pathway. Your liver processes circulating estrogens through a two-phase process. In Phase II, estrogen is conjugated, meaning a glucuronic acid molecule is attached to it. This conjugation essentially deactivates the estrogen and marks it for excretion. The conjugated estrogen is then secreted into bile and sent to the intestines, where it is supposed to leave the body through stool.

But in the gut, beta-glucuronidase-producing bacteria can cleave that glucuronic acid tag off. When they do, the estrogen becomes deconjugated, which means it is active again and can be reabsorbed through the intestinal wall back into the bloodstream. This process is called enterohepatic recirculation, and it is a normal part of estrogen metabolism. The question is how much recirculation happens, and that depends largely on how much beta-glucuronidase your gut bacteria are producing.

What happens when beta-glucuronidase activity is too high?

When the estrobolome is overactive, meaning gut bacteria are producing high levels of beta-glucuronidase, more estrogen gets deconjugated and reabsorbed. This leads to higher circulating estrogen levels than the body intended. A 2016 study by Kwa et al. in the Journal of the National Cancer Institute found that postmenopausal women with less diverse gut microbiomes had higher beta-glucuronidase activity and higher levels of circulating deconjugated estrogens. The study specifically linked this pattern to increased breast cancer risk.

Elevated estrogen from excessive recirculation has been implicated in several conditions. In endometriosis, estrogen fuels the growth and inflammation of endometrial tissue outside the uterus. In estrogen-receptor-positive breast cancer, more circulating estrogen means more fuel for estrogen-sensitive tumors. And in certain presentations of PCOS, estrogen dominance relative to progesterone can worsen symptoms like heavy periods and endometrial thickening.

It is important to note that the estrobolome is not the sole cause of any of these conditions. Genetics, ovarian function, body fat (adipose tissue also produces estrogen), and liver metabolism all play significant roles. But the estrobolome adds a layer that, until recently, was not part of the clinical conversation at all.

What happens when beta-glucuronidase activity is too low?

The conversation about the estrobolome tends to focus on estrogen excess, but the system can malfunction in the other direction too. If gut dysbiosis leads to a sharp reduction in beta-glucuronidase-producing bacteria, less estrogen gets recirculated and more gets excreted. This can contribute to lower circulating estrogen levels than the body needs.

Low estrogen states have their own set of consequences. Estrogen plays protective roles in bone density, cardiovascular health, cognitive function, and vaginal and urinary tract health. In postmenopausal women, where ovarian estrogen production has already dropped dramatically, a poorly functioning estrobolome could compound estrogen deficiency. This is a newer area of research and the clinical data are limited, but the theoretical framework is sound and several research groups are investigating it (Baker et al., 2017).

Antibiotic use is one well-documented cause of acute estrobolome disruption. Adlercreutz et al. showed in 1984 that broad-spectrum antibiotics significantly reduced urinary estrogen excretion, consistent with reduced enterohepatic recirculation due to loss of beta-glucuronidase-producing bacteria. This effect was temporary in most cases but raises questions about what happens with repeated or prolonged antibiotic courses.

Estrobolome, PCOS, and endometriosis: what the research says

PCOS and endometriosis are two of the most common hormonal conditions in reproductive-age women, affecting roughly 10% and 10% of that population, respectively. Both have complex, multifactorial causes. And both have emerging connections to gut health that go beyond coincidence.

In PCOS, the relationship is somewhat indirect. PCOS is primarily characterized by androgen excess and insulin resistance, not estrogen excess per se. However, estrogen and androgen metabolism are interconnected. Aromatase, the enzyme that converts androgens to estrogens, is present in both ovarian tissue and adipose tissue. Altered estrobolome activity could influence the estrogen-to-androgen ratio, which in turn affects the hormonal feedback loops that drive PCOS symptoms. Several studies have found that women with PCOS have distinct gut microbiome profiles with reduced diversity (Lindheim et al., 2017), though whether these differences are a cause or consequence of the hormonal disruption is still debated.

For endometriosis, the connection is more direct. Endometriosis is an estrogen-dependent disease, meaning endometrial implants need estrogen to grow, survive, and cause inflammation. Elevated circulating estrogen from high beta-glucuronidase activity could provide additional fuel for these implants. Laschke and Menger published a 2016 review in the Annals of the New York Academy of Sciences proposing that gut dysbiosis could promote endometriosis progression through both estrogen recirculation and immune dysregulation. The gut microbiome influences systemic inflammation through bacterial lipopolysaccharide (LPS) translocation, and chronic low-grade inflammation is a hallmark of endometriosis.

What influences your estrobolome activity?

Several modifiable and non-modifiable factors affect how much beta-glucuronidase your gut bacteria produce. Understanding these can help you think about gut health in a more specific way than general advice about eating yogurt.

What helps with tracking hormonal and gut symptoms together?

One of the most practical steps you can take is connecting the dots between your gut symptoms and your hormonal patterns. Many women notice that bloating, constipation, or diarrhea fluctuate with their menstrual cycle, but they track these in separate mental categories. When you start logging digestive symptoms alongside cycle data, patterns often emerge that neither you nor your doctor would have noticed otherwise.

A symptom tracking tool like GLP1Gut can help you record both GI symptoms and cycle phase in one place, making it easier to spot correlations and bring organized data to medical appointments. This kind of tracking does not replace clinical testing, but it gives your provider real information to work with instead of vague recollections about when things felt off.

Beyond tracking, the most evidence-supported strategies for supporting estrobolome function are also the most boring ones: eat a high-fiber diet rich in diverse plant foods, limit unnecessary antibiotic use, manage stress, and limit alcohol. These are not novel recommendations, but they are grounded in the actual biology of how your gut processes estrogen.

What about probiotics for estrogen balance?

You will find supplements marketed as estrobolome-supporting or hormone-balancing probiotics online. The marketing is well ahead of the evidence. As of 2026, no randomized controlled trial has demonstrated that a specific probiotic strain meaningfully alters estrobolome function or circulating estrogen levels in a clinically significant way. Some in vitro and animal studies have shown that certain Lactobacillus and Bifidobacterium strains can modulate beta-glucuronidase activity, but translating that to human outcomes is a different matter entirely.

Calcium-D-glucarate is another supplement frequently promoted for estrogen metabolism. It is a natural inhibitor of beta-glucuronidase, and the theory is that supplementing it could reduce estrogen recirculation. Animal studies support this mechanism (Walaszek et al., 1986), but human clinical data are sparse. It is not harmful at typical supplement doses, but calling it a proven estrogen management tool overstates what we know.

The honest summary is this: your gut microbiome matters for estrogen metabolism, and that is well-established science. But targeted interventions to manipulate the estrobolome are still in early research stages. In the meantime, general gut health practices, particularly dietary fiber and microbial diversity, are your best bet based on current evidence.